ADAPTIN BIO, INC. Annual Report - How They Did This Year

I’m writing this guide to help you understand how Adaptin Bio performed this year. My goal is to explain their complex financial filings in plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Adaptin Bio is a clinical-stage biotech company focused on treating brain tumors. They use a "hitchhiking" platform that utilizes the body’s own immune cells to transport medicine directly to tumors, bypassing the blood-brain barrier.

Their lead drug, APTN-101, is designed to treat glioblastoma. It acts like a "Trojan horse," sneaking past the body’s natural defenses to deliver treatment directly to aggressive cancer cells.

2. Major wins: Moving toward human trials

The company successfully transitioned from lab testing to active clinical development this year. Key milestones include:

• Regulatory Clearance: The FDA cleared the company to move from a single-dose safety study to a multi-dose Phase 1/2a trial.
• Clinical Initiation: Three major medical centers have approved patient enrollment, which is scheduled to begin in March 2026.
• Manufacturing Readiness: The company has completed the production of enough APTN-101 to treat the first 15 patients.
• Intellectual Property: They currently hold 12 U.S. patents, providing protection for their technology through 2041.

3. Financial performance and health

Adaptin Bio is currently in the development phase and reported $0 in sales for 2025. The company recorded a loss of $42.5 million this year, driven by $31.2 million in research and development and $11.3 million in general business expenses.

At the end of the year, the company held $18.8 million in cash. With a monthly burn rate of approximately $3.2 million, current cash reserves are projected to last until the third quarter of 2026. To sustain operations and complete clinical trials, management has stated a requirement to raise between $50 million and $75 million within the next year.

4. Key risks: The "Biotech Gamble"

Investing in early-stage biotech is high-stakes. Here are the primary factors to consider:

• "Going Concern" Risk: Auditors have noted that the company may require additional capital to continue operations over the next 12 months.
• Clinical Trial Success: APTN-101 is in early-stage testing. Historically, the path from early clinical trials to FDA approval is difficult, and success is never guaranteed.
• Dilution: To secure the necessary $50 million to $75 million in funding, the company will likely issue and sell additional shares. This would reduce the ownership percentage of current shareholders.
• Competition: Adaptin Bio competes with large pharmaceutical companies that possess significantly greater financial resources and clinical development experience.

5. The Bottom Line

Adaptin Bio represents an "all-or-nothing" investment opportunity. While they have achieved significant progress by securing FDA approval for their upcoming trials, their immediate financial future depends on their ability to raise capital. This is not a passive investment; it is a high-risk, high-reward play centered on the success of APTN-101. If you are considering an investment, keep a close watch on the clinical data updates expected in late 2026, as these results will likely be the primary driver of the company's valuation.